imatinib mesylate has been researched along with Intestinal Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacigalupo, A; Balduzzi, A; Cimminiello, M; Gabrielli, A; Gini, G; Leoni, P; Locatelli, F; Mordini, N; Olivieri, A; Raimondi, R; Sanna, A; Zecca, M | 1 |
| Artz, AS; Liu, H | 1 |
1 trial(s) available for imatinib mesylate and Intestinal Diseases
| Article | Year |
|---|---|
Imatinib for refractory chronic graft-versus-host disease with fibrotic features.
Topics: Adolescent; Adult; Benzamides; Child; Female; Fibrosis; Graft vs Host Disease; Humans; Imatinib Mesylate; Intestinal Diseases; Lung Diseases; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Treatment Outcome | 2009 |
1 other study(ies) available for imatinib mesylate and Intestinal Diseases
| Article | Year |
|---|---|
Reduction of imatinib absorption after gastric bypass surgery.
Topics: Antineoplastic Agents; Benzamides; Biliopancreatic Diversion; Female; Gastric Bypass; Humans; Imatinib Mesylate; Intestinal Absorption; Intestinal Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Obesity; Piperazines; Pyrimidines | 2011 |